scholarly journals 1. CLINICAL STUDY OF EFFECTS OF INJ.CAROVERINE AND GINKGO BILOBA EXTRACT IN COMHLEAR SYNPATIC TINNITUS

2017 ◽  
Vol VOLUME 5 (VOLUME 5 NUMBER 2 JULY 2017) ◽  
pp. 1-10
Author(s):  
Mohammad Aftab
Keyword(s):  
Placebo Group ◽  
Ginkgo Biloba ◽  
Ginkgo Biloba Extract ◽  
Antagonistic Activity ◽  
Pharmacological Therapy ◽  
Drug Infusion ◽  
Retraining Therapy ◽  
Group 3 ◽  
Group 2 ◽  
Ginko Biloba

Tinnitus (ringing in the ear), is the most common problem encountered in every day of otolaryngology practices. Considerable variations exist in tinnitus prevalence with gender and age. It affects patient's life-style, general health as well as emotional status. The most common variety of tinnitus, cochlear synaptic tinnitus is diagnosed with the help of various audiological tests. There is no standardised treatment till date yet Tinnitus Retraining Therapy, medical therapy in form of psychotherapy or pharmacological therapy are commonly used one. Ginko biloba extract suggest greater and faster relief as compared to placebo. Recently Caroverine, a spasmolytic drug, having glutamate antagonistic activity is used for Tinnitus treatment. A randomised comparative study was designed to establish effects of Caroverine and Ginko biloba extract in treatment of Cochlear Synaptic Tinnitus. METHOD: 86 diagnosed patients of cochlear synaptic Tinnitus were treated with Inj Caroverine (group 1, n=22) and placebo (group 2, n=21), Ginkgo biloba extract ( group 3, n=22) and placebo (group 4, n=21) and followed up at 1 month ,3 months and 6 months and improvements were evaluated in terms of Tinnitus Grading and Tinnitus Matching. Statistical analysis was done using statistical software SPSS. The baseline profile and any improvement after treatment between groups were compared using paired/ANOVA test. RESULT: In our study 54.4% (12 out of 22.) patients responded immediately after infusion of Caroverine and remained effective at end of 1,3 and 6 months after drug infusion while 13.6% (3 out of 21) patients responded in placebo group and reverted back to pretreatment level on subsequent follow ups. In Ginkgo biloba group 31.8% (7 out of 22) patients responded at one month followup, while none responded in placebo group. These responders showed further improvement in Tinnitus Matching and Tinnitus Grading at 3 months but a plateau occurred at followup at 6 month without further improvement. Two patients were cured in group 3 (Gingko biloba). CONCLUSION: Caroverine immediately improves tinnitus grading and matching and provides immediate relief in reducing the severity of tinnitus. Ginkgo biloba extract takes longer time to improve tinnitus but it provides greater relief on long term follow-up It is finally suggested that inj. Caroverine should be given in severe cases of tinnitus to reduce its severity immediately and then patient should be put on Ginkgo biloba extract for a period of 3 months to provide sustained and long lasting relief. KEY WORDS: Cochlear Synaptic Tinnitus, Tinnitus Matching. Tinnitus Grading, Caroverine, Ginko biloba.

EVALUATION OF EFFICACY OF SILODOSIN VERSUS SILODOSIN WITH DEFLAZACORT IN EXPULSION OF LOWER URETERIC CALCULI

2021 ◽  
pp. 30-33
Author(s):  
Dev Yadav ◽  
P.N Agarwal ◽  
Sham Lal Singla ◽  
Kanwar Singh Goel ◽  
R. Talukdar ◽  
...  
Keyword(s):  
Plain Radiograph ◽  
Pharmacological Therapy ◽  
Urinary Stones ◽  
Controlled Study ◽  
Expulsion Rate ◽  
Ureteric Calculi ◽  
Group 3 ◽  
The Mean ◽  
Group 2 ◽  
Group 1

Objectives: To compare the efcacy of silodosin versus silodosin with deazacort in expulsion of lower end ureteric calculi, in terms of episodes of pain,stone expulsion rate,stone expulsion time ,analgesic requirements and side effects Introduction: Ureteric calculi represent 20% of urinary stones. Ureteroscopy and Shock wave lithotripsy proven the method of treatments for lower ureteric stones; however, they are expensive and not risk free. Aconservative approach is becoming more popular as a result of advances in pharmacological therapy which reduces the symptoms and helps in stone expulsion. We performed a randomized controlled prospective study to evaluate the efcacy of Deazacort in combination with alpha blocker silodosin in medical management of symptomatic lower Ureteric stones of ≤8 mm size. Material and methods: A prospective randomised controlled study was conducted on 60 patients, age ≥ 18 , who had unilateral lower ureteric stone of ≤ 8 mm. Patients were divided into three groups. Group 1 received silodosin 8 mg for 14 days,Group 2 received silodosin 8 mg plus deazacort 30mg daily for 14 days and Group 3 (control) received diclofenac potassium (75 mg ) when required. The patients were followed-up by ultrasonography ,plain radiograph KUB and computed tomography (in some cases). Results: There was a higher stone expulsion rate of 95% in Group 2 as compared to Group 1(85%) and Group 3(35%) . Group 2 showed a signicant advantage for stone expulsion time ,decreased pain episodes and analgesic use. Two patients, one in group 1 and group 2, reported retrograde ejaculation. Conclusion: The results showed that silodosin with deazacort , increases the stone expulsion rate, decrease the stone expulsion time, decreases the mean number of pain episodes and decreases the mean analgesic dosage requirement. But larger study is required to establish its efcacy for expulsion rate which will be statistically signicant.

Abstract 10770: Curcumin Mitigates the Severity of Post-Resuscitation Myocardial Dysfunction Caused by Epinephrine in a Rat Cardiac Arrest Model

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Zhengfei Yang ◽  
Jiangang Wang ◽  
Lu Yin ◽  
Shen Zhao ◽  
Ziren Tang ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Placebo Group ◽  
Ventricular Fibrillation ◽  
Myocardial Function ◽  
Myocardial Dysfunction ◽  
Sprague Dawley ◽  
Successful Resuscitation ◽  
Sprague Dawley Rats ◽  
Group 3 ◽  
Group 2

Introduction: Epinephrine significantly increases the severity of post-resuscitation myocardial dysfunction (PRMD) and reduces the duration of survival. The cardioprotective effect of curcumin against catecholamine-induced cardiotoxicity has been established. In the present study, we investigated the effects of curcumin on PRMD caused by epinephrine in a rat model of cardiac arrest. Hypothesis: Curcumin reduces the severity of PRMD caused by epinephrine. Methods: Twenty-four male Sprague-Dawley rats weighing between 450-550g were randomized into three groups: 1) Placebo group; 2) Epinephrine (20ug/kg) group; 3) Curcumin (100 mg/kg) pretreatment + epinephrine (20ug/kg) group. Ventricular fibrillation (VF) was then induced. After 8 mins of VF, CPR was initiated for 8 mins, and defibrillation was then attempted. Myocardial function was measured by echocardiography at baseline and hourly for 4 hours following successful resuscitation. Results: All animals except for two in the placebo group were resuscitated. Post-resuscitation myocardial function was significantly impaired in all animals. Significantly worse myocardial function was observed in the Epinephrine group in comparison with the two other groups (Figure). However, myocardial function was significantly better in the animals treated with curcumin when compared with those in the two other groups (Figure). Conclusion: In a rat cardiac arrest model, curcumin reduced the severity of PRMD caused by epinephrine.

Results of trimethoprim-sulfamethoxazole prophylaxis in ventriculostomy and shunting procedures

1985 ◽  
Vol 62 (5) ◽  
pp. 694-697 ◽  
Author(s):  
Göran C. Blomstedt
Keyword(s):  
Placebo Group ◽  
Infection Rates ◽  
Group 14 ◽  
Content Type ◽  
Group 4 ◽  
Antibiotic Group ◽  
Group 3 ◽  
Group 2 ◽  
To Receive ◽  
Group 1

✓ The author reports the results of a study to assess the effectiveness of a trimethoprim-sulfamethoxazole combination as prophylaxis in ventriculostomy or shunting operations. Between 1980 and 1983, 122 patients undergoing shunting procedures were randomly assigned to receive trimethoprim-sulfamethoxazole (Group 1, 62 cases) or a placebo (Group 2, 60 cases). The same regimen was followed at each operation, and the patients were followed for a minimum of 6 months. There was a higher infection rate in the placebo group (14 of 60 patients compared with 4 of 62 patients in the antibiotic group, p < 0.01). The antibiotic protected against early infections (nine of the 60 patients in Group 2 against none of the patients in Group 1), but not against late infections (four of the 62 in Group 1 compared with five of the 60 in Group 2). During the same period, 52 patients undergoing ventriculostomy only were also randomly assigned to receive trimethoprim-sulfamethoxazole (Group 3) or placebo (Group 4). There were no differences in the infection rates between these groups (one of 25 in Group 3 as against one of 27 in Group 4).

scholarly journals Anticlastogenic Effect of Ginkgo Biloba Extract in Graves’ Disease Patients Receiving Radioiodine Therapy

2007 ◽  
Vol 92 (11) ◽  
pp. 4286-4289 ◽  
Author(s):  
A. Dardano ◽  
M. Ballardin ◽  
M. Ferdeghini ◽  
E. Lazzeri ◽  
C. Traino ◽  
...  
Keyword(s):  
Placebo Group ◽  
Clinical Outcome ◽  
Ginkgo Biloba ◽  
Radioiodine Therapy ◽  
Statistical Significance ◽  
Ginkgo Biloba Extract ◽  
131I Therapy ◽  
Graves Disease ◽  
Egb 761 ◽  
Significant Difference

Abstract Background: Chromosomal damage, as assessed by clastogenic factors (CFs) and micronuclei (MN) appearance, after radioiodine therapy of Graves’ disease has been reported. Objective and Methods: Our objective was to evaluate the effect of Ginkgo biloba extract (EGb 761) supplementation on the time course (up to 120 d) of CFs and MN appearance in lymphocytes from patients with Graves’ disease after iodine-131 (131I) therapy. Patients were randomly assigned to EGb 761 or placebo, in a blinded manner. Results: In the placebo group, MN increased early (P &lt; 0.001) after 131I, peaking at the 21st day (P = 0.0003) and declining thereafter. In EGb 761-treated patients, MN increased early (P &lt; 0.05), while returning toward baseline value thereafter. Therefore, mean MN increment was significantly higher in the placebo group as compared with EGb 761-treated patients (P &lt; 0.01). Moreover, an early (P &lt; 0.0001) and sustained (up to 35 d; P &lt; 0.001) MN increase induced by CFs was observed in the placebo group. Conversely, in EGb 761-treated patients, MN increase induced by CFs never reached the statistical significance; therefore, the mean of the MN increments was significantly lower than in placebo (P &lt; 0.05). A significant positive correlation between MN maximum increment and the bone marrow dose was observed in the placebo group only (P = 0.03). No significant difference was observed in clinical outcome between the two groups. Conclusions: EGb 761 supplementation neutralized genotoxic damage induced by radioiodine treatment, without affecting the clinical outcome. Although 131I therapy is generally safe, our data suggest that Gingko biloba extracts may prevent genetic effects of radioiodine therapy for hyperthyroid Graves’ disease.

Monocyte Chemotactic Protein - 1 in a Randomized Placebo-Controlled Study of Canine Plasmacytic-Lymphocytic Colitis

2002 ◽  
Vol 15 (2) ◽  
pp. 107-112 ◽  
Author(s):  
T.S. Rallis ◽  
S. Frydas ◽  
N. Soubasis ◽  
K.K. Adamama-Moraitou ◽  
D. Tontis
Keyword(s):  
Fatty Acids ◽  
Placebo Group ◽  
Controlled Study ◽  
Colonic Tissue ◽  
Monocyte Chemotactic Protein ◽  
Chemotactic Protein ◽  
Group 3 ◽  
Therapeutic Protocols ◽  
Group 2 ◽  
Group 1

The purpose of this study was to determine serum and colonic monocyte chemotactic protein-1 (MCP-1) concentration in dogs with plasmacytic-lymphocytic (PL) colitis, as well as to demonstrate if the concentration of MCP-1 may be an accurate diagnostic and prognostic marker for PL colitis in dogs receiving three different therapeutic protocols. Serum and colonic MCP-1 concentration were measured in 18 dogs with PL colitis and in 6 controls. Dogs with PL colitis were randomly divided in 3 groups and for a period of 30 days received the following: Group 1, sulfasalazine, prednisone and placebo; Group 2, placebo and Ω3/Ω6 fatty acids, and Group 3, sulfasalazine, prednisone and Ω3/Ω6 fatty acids. Colonic and serum MCP-1 concentration were determined at the beginning and at the end of this period. Serum MCP-1 concentrations at the beginning were not significantly increased in dogs with PL colitis compared to the controls. On the contrary, colonic tissue MCP-1 concentrations at the beginning were significantly increased in the same dogs compared to the controls. Moreover, the colonic tissue MCP-1 concentration in the dogs of group 3 was significantly decreased (P<0.001) at the end of the experiment. The same observations were obtained from dogs of groups 1 and 2, in which the colonic MCP-1 concentration also significantly decreased (P<0.01). These data demonstrate that in canine PL colitis, colonic MCP-1 concentration is increased in comparison to those of controls and suggest that the colonic MCP-1 concentration may aid in the diagnosis of canine PL colitis.

Effects of an oral androgen on muscle and metabolism in older, community-dwelling men

2003 ◽  
Vol 284 (1) ◽  
pp. E120-E128 ◽  
Author(s):  
E. Todd Schroeder ◽  
Atam Singh ◽  
Shalender Bhasin ◽  
Thomas W. Storer ◽  
Colleen Azen ◽  
...  
Keyword(s):  
Placebo Group ◽  
Muscle Strength ◽  
Hdl Cholesterol ◽  
Community Dwelling ◽  
Upper Body ◽  
Treatment Groups ◽  
Body Strength ◽  
Upper Body Strength ◽  
Group 3 ◽  
Group 2

To determine whether oxymetholone increases lean body mass (LBM) and skeletal muscle strength in older persons, 31 men 65–80 yr of age were randomized to placebo ( group 1) or 50 mg ( group 2) or 100 mg ( group 3) daily for 12 wk. For the three groups, total LBM increased by 0.0 ± 0.6, 3.3 ± 1.2 ( P < 0.001), and 4.2 ± 2.4 kg ( P < 0.001), respectively. Trunk fat decreased by 0.2 ± 0.4, 1.7 ± 1.0 ( P = 0.018), and 2.2 ± 0.9 kg ( P= 0.005) in groups 1, 2, and 3, respectively. Relative increases in 1-repetition maximum (1-RM) strength for biaxial chest press of 8.2 ± 9.2 and 13.9 ± 8.1% in the two active treatment groups were significantly different from the change (−0.8 ± 4.3%) for the placebo group ( P < 0.03). For lat pull-down, 1-RM changed by −0.6 ± 8.3, 8.8 ± 15.1, and 18.4 ± 21.0% for the groups, respectively (1-way ANOVA, P = 0.019). The pattern of changes among the groups for LBM and upper-body strength suggested that changes might be related to dose. Alanine aminotransferase increased by 72 ± 67 U/l in group 3 ( P < 0.001), and HDL-cholesterol decreased by −19 ± 9 and −23 ± 18 mg/dl in groups 2 and 3, respectively ( P = 0.04 and P = 0.008). Thus oxymetholone improved LBM and maximal voluntary muscle strength and decreased fat mass in older men.

Ultrastructural Evaluation of the Effects of Vitamin D and Parathyroid Hormone On Bone of Thyroparathyroidectomized Rats

1973 ◽  
Vol 31 ◽  
pp. 350-351
Author(s):  
S. E. Weisbrode ◽  
C. C. Capen
Keyword(s):  
Vitamin D ◽  
Placebo Group ◽  
Parathyroid Hormone ◽  
Experimental Period ◽  
Group 4 ◽  
Low Calcium Diet ◽  
Group 3 ◽  
Group 2 ◽  
Hydroxyproline Excretion ◽  
Group 1

To evaluate the effects of vitamin D (VD) and parathyroid hormone (PTH) individually and in combination on bone, adult male thyroparathyroidectomized (TXPTX) ruts fed a low calcium diet (0.05% CA) were administered 7,500 I.U. VD/day (group 1), 50 USP units PTH/day (group 2), 7,500 I.U. VD and 50 USP units PTH/day (group 3), or placebo (group 4). All animals were supplemented daily with 10 g sodium levothyroxine for the 7 day experimental period. Undemineral ized tibial bone was evaluated electron microscopically and these findings were correlated with changes in terminal serum calcium (CA), serum phosphorus (P) and urinary total hydroxyproline excretion, expressed as a ratio to creatinine (HOP/CR).

MORINDA CITRIFOLIA EXTRACT MOUTHWASH AS ANTIGINGIVITIS

2016 ◽  
Vol 19 (2) ◽  
pp. 102-109
Author(s):  
Nila Kasuma ◽  
Fildzah Nurul Fajrin ◽  
Yufri Aldi
Keyword(s):  
Placebo Group ◽  
Early Stage ◽  
Morinda Citrifolia ◽  
Clinical Effects ◽  
Mild Form ◽  
Fruit Extract ◽  
The Public ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

Gingivitis is a inflamatory mild form of periodontal disease in gingiva. The early stage of gingivitis characterized by the accumulation of plaque, leukocytes, and PMN. Noni (Morinda citrifolia L.) is known to have anti-inflammatory compositions which also affects the activity of leukocytes during inflammation. The research objective was to analyze the clinical effects of mouthwash that contains extracts of noni (Morinda citrifolia L.) on leukocyte levels in the saliva in patients with gingivitis, in order to obtain traditional mouthwash that is economical, readily available, and effective in reducing gingivitis and can be used by the public. Extracts of noni fruit (Morinda citrifolia L.) is given in the form of mouthwashes used for 7 days in a row. Observations conducted on three groups of respondents: group 1 using mouthwash placebo, group 2 using mouthwash noni fruit extract 5%, and group 3 using chlorhexidine 0.1%. The use of mouthwash done in the morning and at night before bed as much as 15 ml for 30 seconds. The results showed a decrease in the number of leukocytes in the group treated with placebo cyst, 5% noni fruit extract, and chlorhexidine 0.1% (p <0.05). Both test preparations equally decreased the number of leukocytes in gingival sulcus in gingivitis patients.

Dopamine receptors modulate sodium excretion in denervated kidney

1986 ◽  
Vol 250 (6) ◽  
pp. F1033-F1038 ◽  
Author(s):  
P. A. Jose ◽  
R. A. Felder ◽  
R. R. Holloway ◽  
G. M. Eisner
Keyword(s):  
Placebo Group ◽  
Sodium Excretion ◽  
Sch 23390 ◽  
Water Excretion ◽  
Group 3 ◽  
Group 2 ◽  
Wistar Kyoto ◽  
Pentobarbital Sodium Anesthesia ◽  
Group 1

Dopamine (DA) modulates sodium excretion by the innervated kidney. To examine the role of DA in the denervated (DNX) kidney the effects of the DA1/DA2 antagonist cis-flupenthixol (group 2, n = 7) (10 nmol X kg-1 X min-1), given intravenously in saline-loaded Wistar-Kyoto rats after acute unilateral left DNX, were compared with a placebo group (group 1, n = 7) and a group that received the DA1 antagonist SCH 23390 (group 3, n = 7) at 2.5 nmol X kg-1 X min-1. Pentobarbital sodium anesthesia was employed. Adequacy of DNX was assessed by a natriuresis and decrease in renal norepinephrine content in the DNX kidney and an antinatriuresis in the innervated right kidney. Mean arterial pressure slightly decreased in the placebo group (group 1, 106.7 +/- 2.2 vs. 99.3 +/- 2.4 mmHg) and after cis-flupenthixol (group 2, 108.8 +/- 2.7 vs. 92.8 +/- 1.8 mmHg) but not after SCH 23390 (group 3, 105.6 +/- 1.6 vs. 103 +/- 1.1 mmHg). Glomerular filtration rate was not affected by placebo or SCH 23390 in the DNX or innervated kidney but did slightly decrease after cis-flupenthixol in the DNX kidney. Sodium and water excretion after drug administration differed among the groups. In the DNX kidney urine flow decreased only in group 2, whereas fractional sodium excretion decreased modestly (P less than 0.05 paired t test) with SCH 23390 (3.53 +/- 0.34 vs. 2.89 +/- 0.20%) markedly with cis-flupenthixol (3.18 +/- 0.50 vs. 1.21 +/- 0.18%) and was unchanged in the placebo group (3.25 +/- 0.61 vs. 3.45 +/- 0.45%).(ABSTRACT TRUNCATED AT 250 WORDS)

Sign in / Sign up

Export Citation Format

Share Document